US FDA Finalizes Nonclinical Test Guidance Intended To Spur NDAs For Novel NRTs

Final guidance tracks nearly word-for-word with draft document detailing the agency’s thinking on animal studies for novel NRTs the Center for Drug Evaluation and Research published in August 2018.

The US Food and Drug Administration’s final guidance on nonclinical studies to support drug applications for smoking cessation or similar indications is largely unchanged from the draft, which signaled the extent of the agency’s interest in novel nicotine replacement therapy products, such as e-cigarettes.

The final guidance announced on 28 October tracks nearly word-for-word with the draft document detailing the agency’s thinking on...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation